Designing new therapeutic options for heart disease
CardioMech is developing a technology designed to treat a clear unmet clinical need – patients with Mitral Valve Regurgitation.
The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail. The 3 available therapy options for these patients (open heart surgery, edge-to-edge repair, and TA chordal repair) are insufficient. Today 4,000,000 patients globally suffer from severe, symptomatic DMR and there are 220,000 new patients each year.
Caution: The CardioMech device is in the early R&D development phase and is NOT approved or cleared by the FDA or any other regulatory body in any region of the world.